| |||||||
Type Mutant Stock; Targeted Mutation; Additional information on Genetically Engineered Mutant Mice. Species laboratory mouse Donating Investigator David Russell, Univ of Texas Southwest Med Ctr Dallas Description
Mice homozygous for the Epas1tm1Rus targeted mutation develop normally until embryonic day 11.5. Beginning at embryonic day 12.5 the ratio of homozygous embryos begins to decline and by day 16.5 there are no viable mutant embryos. Overall morphological development, including the circulatory system, is normal. Of particular interest however, is a pronounced bradycardia in homozygous mutant mice. Catecholamine levels in homozygous mutant mice are also significantly lower than wildtype controls. Administration of the catecholamine precursor DOPS to pregnant females rescues approximately 40% of mutant embryos. Embryos that survive to birth appear runted, fail to nurse, and die within 24 hours of birth. These results suggest a pivotal role of EPAS1 in catecholamine homeostasis. Heterozygous mice from this strain contain a modified lacZ gene in the targeting construct. This characteristic makes this strain useful as a marker for endothelial cells.Development
Disruption of the Epas1 gene was accomplished by homologous recombination in embryonic stem cells with a targeting plasmid in which a modified form of E. coli beta-galactosidase was substituted for exon 2 of the Epas1 gene.
| Wildtype mice from the colony or B6129SF2 mice (Stock No. 101045) may be used as controls. The B6129SF2 mice only provide an approximate genetic match to this B6,129 background. | ||
| Considerations for Choosing Controls | ||
lacZ Expression Strains
View lacZ Expression Strains (178 strains)
Strains carrying other alleles of Epas1
008407 STOCK Epas1tm1Mcs/J View Strains carrying other alleles of Epas1 (1 strain)
Fluorescent Proteins/lacZ Systems
View Mammalian Phenotype Terms
Mammalian Phenotype Terms
assigned by genotype
Epas1tm1Rus/Epas1tm1Rus
either: (involves: 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)
- lethality-prenatal/perinatal
- embryonic lethality during organogenesis (MGI Ref ID J:50964)
- starting at E12.5, homozygous mutant embryos are obtained at a progressively declining Mendelian frequency
- lethality throughout fetal growth and development (MGI Ref ID J:50964)
- no homozygotes are obtained by E16.5; embryos surviving between E12.5 and E15.5 appear grossly normal with no overt morphological defects
- administration of catecholamine precursor DOPS to pregnant females prevents midgestational lethality in ~40% of mutant embryos, whereas L-DOPA fails to do so
- rescued pups are carried to term, but appear runted, fail to suckle, and die within 24 hr after birth
- cardiovascular system phenotype
- congestive heart failure (MGI Ref ID J:50964)
- decreased heart rate (MGI Ref ID J:50964)
- at E12.5, homozygotes exhibit significant bradycardia (average heart rate 26.9 ± 8.0) relative to wild-type embryos (36.0 ± 6.6)
- vasculature congestion (MGI Ref ID J:50964)
- dead homozygotes exhibit congestion of blood in the liver and cardiac outflow tracts; however, no morphological defects are noted in the heart, liver, or placenta at E11.5 or E15.5
- homeostasis/metabolism phenotype
- decreased circulating noradrenaline level (MGI Ref ID J:50964)
- at E12.5, homozygotes exhibit significantly reduced noradrenaline levels (3.21 ± 0.76 ng/mg protein) relative to wild-type embryos (5.42 ± 2.15 ng/mg protein)
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:
Epas1tm1Rus relatedDevelopmental Biology Research
Embryonic Lethality (Homozygous)
Research Tools
lacZ Expression
Cancer Research (endothelial cell marker for neovascularization)
Cardiovascular Research (endothelial cell marker (lacZ) for neovascularization)
Cardiovascular Research (endothelial cell marker for neovascularization)
Developmental Biology Research
Genetics Research (Tissue/Cell Markers: endothelial cell markers for neovascularization)
Genetics Research (Tissue/Cell Markers: endothelial cells)
Cancer Research
Genes Regulating Growth and Proliferation
Cardiovascular Research
Heart Abnormalities (bradycardia)
Hypertension
Hypotension
Cell Biology Research
Genes Regulating Growth and Proliferation
Developmental Biology Research
Embryonic Lethality (Homozygous)
Postnatal Mortality (Homozygous)
Internal/Organ Research
Adrenal Medulla Defects
Heart Abnormalities (bradycardia)
Other Organ Defects (Zuckerkanl)
Research Tools
Cancer Research (endothelial cell marker for neovascularization)
Cardiovascular Research (endothelial cell marker (lacZ) for neovascularization)
Genetics Research (Tissue/Cell Markers: endothelial cells)
| Allele Symbol | Epas1tm1Rus | ||
|---|---|---|---|
| Allele Name | targeted mutation 1, David W Russell | ||
| Allele Type | Targeted (Reporter) | ||
| Common Name(s) | Epas1-; HIF2alphaLacZ; | ||
| Mutation Made By | Hui Tian, Harvard University | ||
| Strain of Origin | 129S7/SvEvBrd | ||
| ES Cell Line Name | JH1 | ||
| ES Cell Line Strain | 129S7/SvEvBrd | ||
| Site of Expression | Targeting construct includes modified lacZ. Useful as a marker for endothelial cells in heterozygotes. | ||
| Gene Symbol and Name | Epas1, endothelial PAS domain protein 1 | ||
| Chromosome | 17 | ||
| Gene Common Name(s) | ECYT4; HIF-2alpha; HIF1 alpha-like factor; HIF2A; HLF; HRF; Hif like protein; MOP2; PASD2; hypoxia inducible transcription factor 2alpha; | ||
| Molecular Note | A lacZ gene was inserted and fused in-frame into exon 2, and was followed by a neomycin selection cassette. Western blot analysis indicated that the expression of wild-type transcript was eliminated from this allele. However, a beta-galactosidase fusionprotein was expressed under the control of the endogenous promoter. [MGI Ref ID J:50964] | ||
Genotyping Protocols
Epas1tm1Rus, STD PCR, vers. 1
Helpful Links
Optimizing PCR Protocols
Tian H; Hammer RE; Matsumoto AM; Russell DW; McKnight SL. 1998. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 12(21):3320-4. [PubMed: 9808618] [MGI Ref ID J:50964]
Epas1tm1Rus relatedDing K; Scortegagna M; Seaman R; Birch DG; Garcia JA. 2005. Retinal Disease in Mice Lacking Hypoxia-Inducible Transcription Factor-2{alpha}. Invest Ophthalmol Vis Sci 46(3):1010-6. [PubMed: 15728559] [MGI Ref ID J:96396]
Dioum EM; Clarke SL; Ding K; Repa JJ; Garcia JA. 2008. HIF-2alpha-haploinsufficient mice have blunted retinal neovascularization due to impaired expression of a proangiogenic gene battery. Invest Ophthalmol Vis Sci 49(6):2714-20. [PubMed: 18281611] [MGI Ref ID J:136883]
Oktay Y; Dioum E; Matsuzaki S; Ding K; Yan LJ; Haller RG; Szweda LI; Garcia JA. 2007. Hypoxia-inducible factor 2alpha regulates expression of the mitochondrial aconitase chaperone protein frataxin. J Biol Chem 282(16):11750-6. [PubMed: 17322295] [MGI Ref ID J:121138]
Scortegagna M; Ding K; Oktay Y; Gaur A; Thurmond F; Yan LJ; Marck BT; Matsumoto AM; Shelton JM; Richardson JA; Bennett MJ; Garcia JA. 2003. Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice. Nat Genet 35(4):331-40. [PubMed: 14608355] [MGI Ref ID J:86736]
Scortegagna M; Ding K; Zhang Q; Oktay Y; Bennett MJ; Bennett M; Shelton JM; Richardson JA; Moe O; Garcia JA. 2005. HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 105(8):3133-40. [PubMed: 15626745] [MGI Ref ID J:98454]
Scortegagna M; Morris MA; Oktay Y; Bennett M; Garcia JA. 2003. The HIF family member EPAS1/HIF-2alpha is required for normal hematopoiesis in mice. Blood 102(5):1634-40. [PubMed: 12750163] [MGI Ref ID J:85299]
Steenhard BM; Freeburg PB; Isom K; Stroganova L; Borza DB; Hudson BG; St John PL; Zelenchuk A; Abrahamson DR. 2007. Kidney development and gene expression in the HIF2alpha knockout mouse. Dev Dyn 236(4):1115-1125. [PubMed: 17342756] [MGI Ref ID J:119808]
Currently there no information available for this strain. This may be due to the supply level of this strain.
| Pricing for USA, Canada and Mexico shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $1900.00
| Pricing for International shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $2470.00
| Standard Supply | Repository-Cryopreserved. Must Be Recovered. Please refer to pricing and supply notes for further information. |
|---|---|
| Supply Notes |
|
| Wildtype mice from the colony or B6129SF2 mice (Stock No. 101045) may be used as controls. The B6129SF2 mice only provide an approximate genetic match to this B6,129 background. | ||
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. THE LABORATORY EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.
In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.
MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.
Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.